Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 2
1986 1
1990 1
1996 1
1997 1
2004 1
2009 1
2010 1
2012 2
2013 2
2016 1
2017 4
2018 3
2019 5
2020 3
2021 6
2022 9
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, Germino R, Menon S, Sun Y, Wang C, Shapiro AB, Kanik KS, Connell CA; ORAL Surveillance Investigators. Ytterberg SR, et al. N Engl J Med. 2022 Jan 27;386(4):316-326. doi: 10.1056/NEJMoa2109927. N Engl J Med. 2022. PMID: 35081280 Clinical Trial.
SIRT1-FOXOs activity regulates diabetic complications.
Jalgaonkar MP, Parmar UM, Kulkarni YA, Oza MJ. Jalgaonkar MP, et al. Among authors: oza mj. Pharmacol Res. 2022 Jan;175:106014. doi: 10.1016/j.phrs.2021.106014. Epub 2021 Nov 29. Pharmacol Res. 2022. PMID: 34856334 Review.
Emerging links between FOXOs and diabetic complications.
Parmar UM, Jalgaonkar MP, Kansara AJ, Oza MJ. Parmar UM, et al. Among authors: oza mj. Eur J Pharmacol. 2023 Dec 5;960:176089. doi: 10.1016/j.ejphar.2023.176089. Epub 2023 Oct 13. Eur J Pharmacol. 2023. PMID: 37838103 Review.
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, Adams DH, Kerr L, Lee C, Shuler CL, Genovese M; SPIRIT-P2 Study Group. Nash P, et al. Lancet. 2017 Jun 10;389(10086):2317-2327. doi: 10.1016/S0140-6736(17)31429-0. Epub 2017 May 24. Lancet. 2017. PMID: 28551073 Clinical Trial.
Autophagy-nutrient sensing pathways in diabetic complications.
Parmar UM, Jalgaonkar MP, Kulkarni YA, Oza MJ. Parmar UM, et al. Among authors: oza mj. Pharmacol Res. 2022 Oct;184:106408. doi: 10.1016/j.phrs.2022.106408. Epub 2022 Aug 18. Pharmacol Res. 2022. PMID: 35988870 Review.
Novel therapeutic targets for epilepsy intervention.
Kambli L, Bhatt LK, Oza M, Prabhavalkar K. Kambli L, et al. Among authors: oza m. Seizure. 2017 Oct;51:27-34. doi: 10.1016/j.seizure.2017.07.014. Epub 2017 Jul 25. Seizure. 2017. PMID: 28772199 Free article. Review.
ER stress response mediates diabetic microvascular complications.
Sankrityayan H, Oza MJ, Kulkarni YA, Mulay SR, Gaikwad AB. Sankrityayan H, et al. Among authors: oza mj. Drug Discov Today. 2019 Dec;24(12):2247-2257. doi: 10.1016/j.drudis.2019.08.003. Epub 2019 Aug 17. Drug Discov Today. 2019. PMID: 31430543 Review.
Biological activities of meroterpenoids isolated from different sources.
Fuloria NK, Raheja RK, Shah KH, Oza MJ, Kulkarni YA, Subramaniyan V, Sekar M, Fuloria S. Fuloria NK, et al. Among authors: oza mj. Front Pharmacol. 2022 Sep 19;13:830103. doi: 10.3389/fphar.2022.830103. eCollection 2022. Front Pharmacol. 2022. PMID: 36199687 Free PMC article. Review.
Cyclin dependent kinase 5: A novel avenue for Alzheimer's disease.
Bhounsule AS, Bhatt LK, Prabhavalkar KS, Oza M. Bhounsule AS, et al. Among authors: oza m. Brain Res Bull. 2017 Jun;132:28-38. doi: 10.1016/j.brainresbull.2017.05.006. Epub 2017 May 17. Brain Res Bull. 2017. PMID: 28526617 Review.
49 results